The Biostatistics Shared Resource (BSR), as a functional unit of the Yale Center for Analytical Sciences (YCAS), was established in 1995 to provide comprehensive, effective, and timely biostatistical support to Yale Cancer Center (YCC) and other YSM investigators. BSR has a highly experienced and interactive team of biostatisticians who work collaboratively with basic, clinical, translational, and population science researchers to advance the frontiers of cancer medicine and public health. The BSR faculty also offer workshops, office consultations, lectures, seminars, Grand Rounds, and courses on study design, analysis methods, and software implementation to medical students, fellows, research staff, and faculty. To provide more tailored cancer biostatistical support and to further strengthen the area of bioinformatics, Dr. Shuangge Ma, was appointed as the Director of BSR in 2016. During our most recent funding period, we have witnessed a significant increase in the demand for biostatistical and bioinformatics support. The growth has been driven by the strengthening of specific programs (such as Developmental Therapeutics ? DT) as well as cancer research overall, by multi-investigator large projects such as the SPOREs as well as R01-type projects. Other notable accomplishments include strengthened expertise in bioinformatics and clinical trials, added expertise in biomedical big data, and additional infrastructure building. In the next project period, the primary goal of the BSR is to further strengthen our biostatistical and bioinformatics support to YCC investigators and projects.
The Specific Aims of BSR are to: (1) Provide robust, comprehensive, and timely biostatistical and bioinformatics support to all YCC investigators; (2) Develop special emphasis on the areas of bioinformatics, clinical trials, and multi-investigator studies (SPOREs, center grants, etc.); (3) Reinforce strong ties with YCC programs, other shared resources, YSPH, YSM, and cancer biostatisticians/programs nationwide; (4) Implement state-of-the-art methods, and develop new methods and software as needed to support cancer research; (5) Continue providing training in standard statistical practice as well as advanced analytic techniques to medical students, fellows, research staff, and faculty, via seminars, Grand Rounds, lectures, and courses. Over time, the BSR has been established as a critical component of YCC, and it will play an increasingly important role in the coming funding period. !

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016359-41
Application #
9989587
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-08-01
Budget End
2021-07-31
Support Year
41
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Kelada, Olivia J; Decker, Roy H; Nath, Sameer K et al. (2018) High Single Doses of Radiation May Induce Elevated Levels of Hypoxia in Early-Stage Non-Small Cell Lung Cancer Tumors. Int J Radiat Oncol Biol Phys 102:174-183
Powles, Ryan L; Redmond, David; Sotiriou, Christos et al. (2018) Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial. JAMA Oncol 4:e181564
Wang, Shi-Yi; Hsu, Sylvia H; Huang, Siwan et al. (2018) Regional Practice Patterns and Racial/Ethnic Differences in Intensity of End-of-Life Care. Health Serv Res 53:4291-4309
Gettinger, S N; Choi, J; Mani, N et al. (2018) A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers. Nat Commun 9:3196
Liu, Huafeng; Li, Xin; Hu, Li et al. (2018) A crucial role of the PD-1H coinhibitory receptor in suppressing experimental asthma. Cell Mol Immunol 15:838-845
Altwerger, Gary; Bonazzoli, Elena; Bellone, Stefania et al. (2018) In Vitro and In Vivo Activity of IMGN853, an Antibody-Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers. Mol Cancer Ther 17:1003-1011
Sanmamed, Miguel F; Chen, Lieping (2018) A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell 175:313-326
Gupta, Swati; Mani, Navin R; Carvajal-Hausdorf, Daniel E et al. (2018) Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer. Lab Invest 98:1076-1083
Bellone, Stefania; Buza, Natalia; Choi, Jungmin et al. (2018) Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement. Clin Cancer Res 24:3282-3291
Altan, Mehmet; Kidwell, Kelley M; Pelekanou, Vasiliki et al. (2018) Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer. NPJ Breast Cancer 4:40

Showing the most recent 10 out of 675 publications